Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

e company reiterated its 2009 financial guidance for revenue and operating expenses initially provided on February 26, 2009.

Revenue

Revenue for 2009, including Actimmune(R) and anticipated milestone payments from Roche, is expected to be in a range of approximately $40 to $50 million. Actimmune revenue represents approximately 50% of this revenue range.

Operating Expenses

R&D expense is anticipated to be in a range of approximately $90 to $100 million, net of development cost reimbursements under the Roche collaboration. Of this amount, approximately 60% is attributed to pirfenidone which includes expenses for CAPACITY, RECAP, the preparation and support of NDA and MAA submissions and manufacturing.

Approximately 35% of the R&D expense is attributed to the company's one-third share of all development expenses incurred by the collaboration with Roche on ITMN-191. The balance of 2009 R&D expense is related to the advancement of a named pirfenidone analog compound, ITMN-520, toward an expected IND filing in mid-2010.

G&A expense is anticipated to be in a range of approximately $35 to $40 million. The G&A guidance range includes approximately $5.0 million of various pirfenidone pre-marketing costs and a similar amount in legal fees associated with a DOJ action against a former InterMune executive covered by an indemnification agreement.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EDT to discuss its financial results for the first quarter 2009, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 95970767. A replay of the webcast and teleconference will be available approximately three hours
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... September 2, 2015 Biovista ... Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. Hierbei ... Genomics Institute. Biovista unterstützt mit seiner ... die Behandlung anderer Krankheiten als denen, für die ... und sein Team bei der Wylder Nation ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... Staff members will be attending Pharma Ed Resources upcoming educational seminar and ... of industry leading speakers, this timely conference will provide Updates & Case Studies ...
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q ... professional commercial video content, to analysis of athletic performance. Producing high-resolution slow-motion ... by too quickly to process with the naked eye. , Slow motion ...
(Date:9/1/2015)... 2, 2015 Swecure, ... Forschung und Entwicklung neuartiger Therapien für Störungen ... und Reizdarm konzentriert, erhält vom US Patent ... neues Medikament patentiert wird. Das Medikament basiert ... Kindern verhindert und Entzündungen vorbeugt.   ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... HARTFORD, Conn., Sept. 15 Genomas(R), a biomedical ... 3-year Phase II Small Business Innovation Research (SBIR) Grant totaling ... Disease, was awarded by the National Institute of Mental Health. ... Ruano, M.D., Ph.D., President/CEO of Genomas and Director of Genetics ...
... , , , ... (Nasdaq: PARD ) today announced that 320 evaluable events (patient ... Efficacy After Relapse) trial, which is being conducted in accordance with a ... evaluating picoplatin in the treatment of small cell lung cancer (SCLC). ...
... , , , ... today the launch of HemoRANK(TM)-TKI, an in vitro assay service ... kinase inhibitors (TKIs) to cause clinical hematotoxicity (myelotoxicity or neutropenia). ... pharmaceutical companies that are developing novel therapeutic TKIs gain insight ...
Cached Biology Technology:Genomas Awarded $1.4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System for Mental Illness 2Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 2Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 3Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 4Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 5ReachBio Launches HemoRANK-TKI Service Package for Predicting Myelotoxicity of New Tyrosine Kinase Inhibitors 2ReachBio Launches HemoRANK-TKI Service Package for Predicting Myelotoxicity of New Tyrosine Kinase Inhibitors 3
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Today a plethora of dog genome-related materials are published, including ... and a series of primary research articles in the ... the publication by Nature of a high-quality draft ... researchers and the public with informative resources about canine genomics ...
... by Duke computer scientists and computational chemists have ... in an intricate three-dimensional puzzle-fit to regulate cell ... anticancer drugs to block the runaway cell division ... Significantly, their insights arose not just from meticulous ...
... scientists who first created "mighty mice" have developed, with ... agent that's more effective at increasing muscle mass in ... now in clinical trials. , The new agent is ... muscle-limiting protein myostatin. In mice, just two weekly injections ...
Cached Biology News:Scientists fetch useful information from dog genome publications 2Scientists fetch useful information from dog genome publications 3Scientists fetch useful information from dog genome publications 4'Computer-chemistry' yields new insight into a puzzle of cell division 2'Computer-chemistry' yields new insight into a puzzle of cell division 3'Computer-chemistry' yields new insight into a puzzle of cell division 4Mouse study: New muscle-building agent beats all previous ones 2
Request Info...
... Calmodulin Sepharose 4B, ... single-step purification of ... proteins.Purification of calmodulin-regulated ... eukaryotic cells. Category: ...
...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
Biology Products: